Developing promising new therapies for patients with rare genetic diseases.
BioMarin is actively pursuing strategies to enhance its exciting product portfolio. The company has a growing product pipeline, with multiple clinical and preclinical IND (Investigational New Drug) candidates in development.
Click on the bar to learn more about each product or product candidate.
*MBC=metastatic breast cancer
*SCLC=small cell lung cancer